Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: J ISAKOS. 2021 May 17;6(5):277–282. doi: 10.1136/jisakos-2020-000551

Table 2.

Values of primary and secondary outcome measures and change scores at each time point (Change calculations: Pre-intervention-Baseline, Post-intervention-Pre-intervention; values are mean ± SD).

Baseline 6 Weeks (Pre-intervention) 12 Weeks (Post-intervention) Change: Baseline to 6 Weeks (control phase) Change: 6 to 12 weeks (intervention phase) P-value*
Composite Y-balance score 88.30 ± 6.89 89.98 ± 6.18 91.27 ± 5.79 1.67 ± 5.34 1.29 ± 4.36 0.16
Hip FPPA (°) 24.25 ± 4.56 22.87 ± 6.01 18.75 ± 6.15 −0.9 ± 4.3 −4.1 ± 7.2 0.0006*
Knee FPPA (°) 22.22 ± 8.65 18.93 ± 10.78 8.54 ± 9.96 −2.3 ± 5.4 −10.4 ± 12.9 <0.0001*
Pain during Y-balance (VAS) 24.39 ± 17.33 28.70 ± 21.16 6.09 ± 10.08 4.30 ± 9.68 −22.6 ± 20.45 <0.0001*#
Lateral Rotator Strength (N) 106.6 ± 21.43 104.6 ± 18.76 111.0 ± 16.40 −1.9 ± 9.9 6.4 ± 10.3 0.003*
Hip Abductor Strength (N) 86.90 ± 26.96 87.03 ± 22.32 96.63 ± 21.67 0.1 ± 18.6 9.6 ± 16.9 0.005*
Hip Extensor Strength (N) 158.7 ± 40.60 160.1 ± 39.29 173.8 ± 38.53 1.4 ± 31.8 13.7 ± 30.2 0.04*

SD = Standard Deviation; FPPA=frontal plane projection angle; N=newtons; VAS= visual analog scale

*

P-value: change during intervention phase compared to change during control phase (statistically significant at 0.05 alpha level)

values reported as % of leg length

#

Prior to analysis, data were log transformed to follow the multivariate normal distribution.